New-onset diabetes after renal transplantation: Risk assessment and management

Diabetes Care

Volumn 35, Issue 1, 2012, Pages 181-188

  Ghisdal, Lidia ^a   Van Laecke, Steven ^b   Abramowicz, Marc J ^a   Vanholder, Raymond ^b   Abramowicz, Daniel ^a  

^a ERASME HOSPITAL   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; CALCINEURIN INHIBITOR; CYCLOSPORIN; CYCLOSPORIN A; EXENDIN 4; GLIMEPIRIDE; GLIQUIDONE; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MEGLITINIDE; METFORMIN; MIGLITOL; NATEGLINIDE; PHENFORMIN; PIOGLITAZONE; PRAMLINTIDE; RAPAMYCIN; REPAGLINIDE; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; TACROLIMUS; THIAZOLIDINE DERIVATIVE; UNINDEXED DRUG; VILDAGLIPTIN; WNT PROTEIN;

BLOOD GLUCOSE MONITORING; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXERCISE; FAMILY HISTORY; GENETIC PREDISPOSITION; GLUCOSE BLOOD LEVEL; HEPATITIS C VIRUS; HUMAN; HYPOMAGNESEMIA; INCIDENCE; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; REVIEW; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOSUPPRESSION; KIDNEY TRANSPLANTATION; RISK ASSESSMENT; RISK FACTORS;

EID: 84859030625     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-1230     Document Type: Review

References (70)

1. Davidson J, Wilkinson A, Dantal J, et al.; International Expert Panel. New-onset diabetes after transplantation: 2003 International Consensus Guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation 2003;75(Suppl.):SS3-SS24
2. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003; 26(Suppl. 1):S5-S20
3. Genuth S, Alberti KG, Bennett P, et al.; Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003;26:3160-3167
4. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010;33(Suppl. 1):S62-S69
5. Sharif A, Baboolal K. Diagnostic application of the A(1c) assay in renal disease. J Am Soc Nephrol 2010;21:383-385
6. Winkelmayer WC, Chandraker A. Pottransplantation anemia: management and rationale. Clin J Am Soc Nephrol 2008;3 (Suppl. 2):S49-S55
7. International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009;32:1327-1334
8. Woodward RS, Schnitzler MA, Baty J, et al. Incidence and cost of new onset diabetes-mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am J Transplant 2003;3:590-598 (Pubitemid 36612842)
9. Vincenti F, Friman S, Scheuermann E, et al.; DIRECT (Diabetes Incidence after Renal Transplantation: Neoral C Monitoring Versus Tacrolimus) Investigators. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007; 7:1506-1514 (Pubitemid 46776239)
10. Burroughs TE, Swindle J, Takemoto S, et al. Diabetic complications associated with new-onset diabetes mellitus in renal transplant recipients. Transplantation 2007;83:1027-1034 (Pubitemid 46659113)
11. Hjelmesaeth J, Hartmann A, Leivestad T, et al. The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events. Kidney Int 2006;69:588-595 (Pubitemid 43164454)
12. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003;3:178-185 (Pubitemid 36323115)
13. Shah T, Kasravi A, Huang E, et al. Risk factors for development of new-onset diabetes mellitus after kidney transplantation. Transplantation 2006;82:1673-1676 (Pubitemid 46035650)
14. Gürsoy M, Güvener N, Köksal R, et al. Impact of HCV infection on development of posttransplantation diabetesmellitus in renal allograft recipients. Transplant Proc 2000;32:561-562 (Pubitemid 30254401)
15. Kamar N, Toupance O, Buchler M, et al. Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation. J Am Soc Nephrol 2003; 14:2092-2098 (Pubitemid 36909917)
16. Hjelmesaeth J, Hartmann A, Kofstad J, et al. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation 1997;64:979-983 (Pubitemid 27446762)
17. Hjelmesaeth J, Sagedal S, Hartmann A, et al. Asymptomatic cytomegalovirus infection is associated with increased risk of new-onset diabetes mellitus and impaired insulin release after renal transplantation. Diabetologia 2004;47:1550-1556 (Pubitemid 39371637)
18. Numakura K, Satoh S, Tsuchiya N, et al. Clinical and genetic risk factors for posttransplant diabetes mellitus in adult renal transplant recipients treated with tacrolimus. Transplantation 2005;80:1419-1424 (Pubitemid 41803623)
19. Sulanc E, Lane JT, Puumala SE, Groggel GC, Wrenshall LE, Stevens RB. New-onset diabetes after kidney transplantation: an application of 2003 International Guidelines. Transplantation 2005;80:945-952 (Pubitemid 41552891)
20. Lutsey PL, Pankow JS, Bertoni AG, Szklo M, Folsom AR. Serological evidence of infections and type 2 diabetes: the Multi- Ethnic Study of Atherosclerosis. Diabet Med 2009;26:149-152
21. Chakkera HA, Hanson RL, Raza SM, et al. Pilot study: association of traditional and genetic risk factors and new-onset diabetes mellitus following kidney transplantation. Transplant Proc 2009;41:4172-4177
22. Porrini E, Delgado P, Bigo C, et al. Impact of metabolic syndrome on graft function and survival after cadaveric renal transplantation. Am J Kidney Dis 2006;48: 134-142
23. Bayer ND, Cochetti PT, Anil Kumar MS, et al. Association of metabolic syndrome with development of new-onset diabetes after transplantation. Transplantation 2010; 90:861-866
24. Cosio FG, Kudva Y, van der Velde M, et al. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int 2005;67:2415-2421 (Pubitemid 41623405)
25. Bergrem HA, Valderhaug TG, Hartmann A, Bergrem H, Hjelmesaeth J, Jenssen T. Glucose tolerance before and after renal transplantation. Nephrol Dial Transplant 2010;25:985-992
26. Van Laecke S, Van Biesen W, Verbeke F, De Bacquer D, Peeters P, Vanholder R. Posttransplantation hypomagnesemia and its relation with immunosuppression as predictors of new-onset diabetes after transplantation. Am J Transplant 2009;9:2140-2149
27. Voight BF, Scott LJ, Steinthorsdottir V, et al.; MAGIC investigators; GIANT Consortium. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet 2010;42: 579-589
28. Lyssenko V, Lupi R, Marchetti P, et al. Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest 2007;117:2155-2163 (Pubitemid 47219560)
29. Ghisdal L, Baron C, Le Meur Y, et al. TCF7L2 polymorphism associates with new-onset diabetes after transplantation. J Am Soc Nephrol 2009;20:2459-2467
30. Kang ES, Kim MS, Kim CH, et al. Association of common type 2 diabetes risk gene variants and posttransplantation diabetes mellitus in renal allograft recipients in Korea. Transplantation 2009;88:693-698
31. Liu Z, Habener JF. Wnt signaling inpancreatic islets. Adv Exp Med Biol 2010;654: 391-419
32. Talmud PJ, Hingorani AD, Cooper JA, et al. Utility of genetic and non-genetic risk factors in prediction of type 2 diabetes: Whitehall II prospective cohort study. BMJ 2010;340:b4838
33. Van Laecke S, Desideri F, Geerts A, et al. Hypomagnesemia and the risk of newonset diabetes after liver transplantation. Liver Transpl 2010;16:1278-1287
34. Corica F, Corsonello A, Ientile R, et al. Serum ionized magnesium levels in relation to metabolic syndrome in type 2 diabetic patients. J Am Coll Nutr 2006;25: 210-215 (Pubitemid 46939845)
35. Guerrero-Romero F, Rodríguez-Morán M. Low serum magnesium levels and metabolic syndrome. Acta Diabetol 2002;39: 209-213 (Pubitemid 35470535)
36. Rodríguez-Morán M, Guerrero-Romero F. Oral magnesium supplementation improves insulin sensitivity and metabolic control in type 2 diabetic subjects: a randomized double-blind controlled trial. Diabetes Care 2003;26:1147-1152 (Pubitemid 36929263)
37. Maes BD, Kuypers D, Messiaen T, et al. Posttransplantation diabetes mellitus inFK-506-treated renal transplant recipients: analysis of incidence and risk factors. Transplantation 2001;72:1655-1661 (Pubitemid 33096741)
38. Pascual J, Zamora J, Galeano C, Royuela A, Quereda C. Steroid avoidance orwithdrawal for kidney transplant recipients. Cochrane Database Syst Rev 2009 (1): CD005632
39. Heit JJ, Apelqvist AA, Gu X, et al. Calcineurin/ NFAT signalling regulates pancreatic betacell growth and function. Nature 2006; 443:345-349 (Pubitemid 44435154)
40. Tamura K, Fujimura T, Tsutsumi T, et al. Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding protein-12 in pancreatic beta-cell. Transplantation 1995;59:1606-1613
41. Heisel O, Heisel R, Balshaw R, Keown P. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant 2004;4:583-595 (Pubitemid 38523581)
42. Webster AC, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus ciclosporin asprimary immunosuppression for kidney transplant recipients:meta-analysis and meta-regression of randomised trial data. BMJ 2005;331:810
43. Duijnhoven EM, Boots JM, Christiaans MH, Wolffenbuttel BH, Van Hooff JP. Influence of tacrolimus on glucose metabolism before and after renal transplantation: a prospective study. J Am Soc Nephrol 2001;12:583-588 (Pubitemid 32180028)
44. Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belataceptbased immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10:535-546
45. Durrbach A, Pestana JM, Pearson T, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 2010;10:547-557
46. Ghisdal L, Bouchta NB, Broeders N, et al. Conversion from tacrolimus tocyclosporine A for new-onset diabetes after transplantation: a single-centre experience in renal transplanted patients and review of the literature. Transpl Int 2008;21:146-151
47. Wyzgal J, Oldakowska-Jedynak U, Paczek L, et al. Posttransplantation diabetus mellitus under calcineurin inhibitor. Transplant Proc 2003;35:2216-2218 (Pubitemid 37194369)
48. Oberholzer J, Thielke J, Hatipoglu B, Testa G, Sankary HN, Benedetti E. Immediate conversion from tacrolimus to cyclosporine in the treatment of posttransplantation diabetes mellitus. Transplant Proc 2005;37:999-1000 (Pubitemid 40590772)
49. Abouljoud MS, Kumar MS, Brayman KL, Emre S, Bynon JS; OLN-452 Study Group. Neoral rescue therapy in transplant patients with intolerance to tacrolimus. Clin Transplant 2002;16:168-172 (Pubitemid 34746392)
50. Johnston O, Rose CL, Webster AC, Gill JS. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol 2008;19:1411-1418
51. Flechner SM, Glyda M, Cockfield S, et al. The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. Am J Transplant 2011; 11:1633-1644
52. Teutonico A, Schena PF, Di Paolo S. Glucose metabolism inrenal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol 2005;16:3128-3135 (Pubitemid 44743511)
53. Bergrem HA, Valderhaug TG, Hartmann A, et al. Undiagnosed diabetes inkidney transplant candidates: a case-finding strategy. Clin J Am Soc Nephrol 2010;5:616-622
54. Wilkinson A, Davidson J, Dotta F, et al. Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin Transplant 2005;19:291-298 (Pubitemid 40711959)
55. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009;9(Suppl. 3):S1-S155
56. Valderhaug TG, Jenssen T, Hartmann A, et al. Fasting plasma glucose and glycosylated hemoglobin in the screening for diabetesmellitus after renal transplantation. Transplantation 2009;88:429-434
57. Ekberg H, Tedesco-Silva H, Demirbas A, et al.; ELITE-Symphony Study. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007;357: 2562-2575 (Pubitemid 350294223)
58. Noël C, Abramowicz D, Durand D, et al. Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients. J Am Soc Nephrol 2009; 20:1385-1392
59. van Gelder T, Le Meur Y, Shaw LM, et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 2006;28:145-154 (Pubitemid 44314941)
60. Lubowsky ND, Siegel R, Pittas AG. Management of glycemia in patients with diabetes mellitus and CKD. Am J Kidney Dis 2007;50:865-879 (Pubitemid 47588565)
61. Nam JH, Lee HC, Kim YH, et al. Identification of glucokinasemutation in subjects with post-renal transplantation diabetes mellitus. Diabetes Res Clin Pract 2000;50: 169-176
62. Rodrigo E, González-Lamuño D, Ruiz JC, et al. Apolipoprotein C-III and Epolymorphisms and cardiovascular syndrome, hyperlipidemia, and insulin resistance in renal transplantation. Am J Transplant 2002;2:343-348 (Pubitemid 36306901)
63. Babel N, Cherepnev G, Kowalenko A, Horstrup J, Volk HD, Reinke P. Nonimmunologic complications and gene polymorphisms of immunoregulatory cytokines in long-term renal transplants. Kidney Int 2004;66:428-432 (Pubitemid 38870121)
64. Rodríguez-Moreno A, Sánchez-Fructuoso AI, Ridao-Cano N, et al. Association of the genetic polymorphisms of the reninangiotensin system with kidney graft long-term outcome: preliminary results. Transplant Proc 2005;37:3716-3717 (Pubitemid 43015143)
65. Bamoulid J, Courivaud C, Deschamps M, et al. IL-6 promoter polymorphism -174 is associated with new-onset diabetes after transplantation. J Am Soc Nephrol 2006; 17:2333-2340 (Pubitemid 44141925)
66. Sánchez-Velasco P, Rodrigo E, Fernández- Fresnedo G, et al. Influence of interleukin-6 promoter polymorphism -174 g/c on kidney graft outcome. Transplant Proc 2010; 42:2854-2855
67. Gençtoy G, Kahraman S, Arici M, et al. The role of proinflammatory cytokine gene polymorphisms for development of insulin resistance after renal transplantation. Transplant Proc 2006;38:521-528
68. Kurzawski M, Dziewanowski K, Kedzierska K, Wajda A, Lapczuk J, Droździk M. Association of transcription factor 7-like 2 (TCF7L2) gene polymorphism with posttransplant diabetes mellitus in kidney transplant patients medicated with tacrolimus. Pharmacol Rep 2011;63:826-833
69. Yang J, Hutchinson II, Shah T, Min DI. Genetic and clinical risk factors of new-onset diabetes after transplantation in Hispanic kidney transplant recipients. Transplantation 2011;91:1114-1119
70. Kurzawski M, Dziewanowski K, Kedzeirska K, Gornik W, Banas A, Drozdzik M. Association of calpain-10 polymorphism and posttransplant diabetes mellitus in kidney transplant patients medicated with tacrolimus. Pharmacogenomics J 2010;10:120-125